16077-78-4

Basic information

• Product Name: 2-Thiazol-2-yl-propan-2-ol
• Synonyms: 2-Thiazol-2-yl-propan-2-ol;??Dimethyl-2-thiazolemethanol;a,a-Dimethyl-2-thiazolemethanol;alpha,alpha-Dimethyl-2-thiazolemethanol
• CAS NO: 16077-78-4
• Molecular Formula: C₆H₉NOS
• Molecular Weight: 143.20676
• Mol File: 16077-78-4.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 210.345°C at 760 mmHg
• Flash Point: 81.014°C
• Appearance: /
• Density: 1.195g/cm³
• Vapor Pressure: 0.115mmHg at 25°C
• Refractive Index: 1.547
• CAS DataBase Reference: 2-Thiazol-2-yl-propan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Thiazol-2-yl-propan-2-ol(16077-78-4)
• EPA Substance Registry System: 2-Thiazol-2-yl-propan-2-ol(16077-78-4)

Safety Data

• Hazardous Substances Data: 16077-78-4(Hazardous Substances Data)

Usage

General Description

2-Thiazol-2-yl-propan-2-ol, also known as thiazoles, is a chemical compound with the molecular formula C5H9NOS. It is a colorless to pale yellow liquid with a faint odor and is considered to be an important building block in the synthesis of various pharmaceutical and agrochemical products. Thiazoles are known to exhibit antimicrobial, antifungal, and antiviral activities, making them valuable in the development of new drugs and treatments. Additionally, they are also used as intermediates in the production of rubber accelerators, dyes, and other organic compounds. Thiazoles are generally considered to have low toxicity and are classified as non-hazardous chemicals.

InChI:InChI=1/C6H9NOS/c1-6(2,8)5-7-3-4-9-5/h3-4,8H,1-2H3

Upstream product

• 3034-53-5 2-bromo-1,3-thiazole 
• 67-64-1 acetone 
• 24295-03-2 2-Acetylthiazole 
• 75-16-1 methylmagnesium bromide 
• 288-47-1 1,3-thiazole 

Downstream Products

• 362719-46-8 4-{2-[(3-cyclobutyloxy-4-difluoromethoxy)phenyl]-2-[5-(2-(1-methyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl)thiazolyl)]ethyl}pyridine N-oxide 
• 362719-42-4 (+/-)-[(3-cyclobutyloxy-4-difluoromethoxy)phenyl]{2-[1-methyl-1-(2-trimethylsilylethoxy)methoxy]ethylthiazol-5-yl}methanol 
• 1026236-19-0 5-[chloro-(3-cyclobutoxy-4-difluoromethoxy-phenyl)-methyl]-2-[1-methyl-1-(2-trimethylsilanyl-ethoxymethoxy)-ethyl]-thiazole 

Relevant articles and documents

SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

HETEROCYCLE-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A', R 2 R 3, R 4 and R are as defined herein. The present i